Lilly's $2.9B Bet on a Disease Most People Have Never Heard Of

Behind MER511, Merida has MER769 in preclinical development for IgE-driven allergic diseases like food allergy, asthma, and chronic hives. There are also earlier kidney and immune-mediated disease programs in the works. But make no mistake: Lilly is paying for the platform concept and MER511's early promise, not a deep portfolio of late-stage assets.

Why Lilly Can't Stop Shopping

This is Lilly's tenth-plus acquisition of 2026. The company has been on a buying spree that would make a teenager with their parents' credit card blush.

The pattern tells a clear story. Lilly's GLP-1/GIP receptor agonists, Mounjaro and Zepbound, have been printing money in obesity and diabetes. But the company clearly doesn't want to be a one-trick pony, no matter how profitable the trick is. So it's been acquiring companies across immunology, oncology, vaccines, sleep medicine, and cell therapy at a breakneck pace.

Consider the 2026 highlight reel: Ventyx Biosciences (NLRP3 inhibitors for inflammation) in January. Orna Therapeutics (in vivo CAR-T for autoimmune disease, up to $2.4 billion) in February. Centessa Pharmaceuticals (sleep disorders) in March. Curevo, LimmaTech Biologics, and Vaccine Company, Inc. all scooped up in May alone for shingles, staph, and Epstein-Barr virus vaccines, respectively. Then Ajax Therapeutics for myelofibrosis. AtaiBeckley in July. And now Merida.

Lilly isn't just diversifying. It's building an entirely new company underneath the GLP-1 cash machine.

A Crowded Dance Floor

Lilly isn't the only pharma giant racing into autoimmune disease. AbbVie dropped $10.9 billion on Apogee Therapeutics in June 2026 and had already acquired Capstan Therapeutics for $2.1 billion in 2025, both aimed at strengthening its immunology lineup as biosimilars chip away at Humira's legacy. Johnson & Johnson is pushing hard with next-generation IL-23 assets. Pfizer is trying to stay relevant as Xeljanz matures.

One industry review counted 29 autoimmune-focused transactions in the recent deal cycle, totaling roughly $48 billion in headline value. R&D partnerships in the space more than doubled in value from 2024 to 2025. Everyone, it seems, wants a piece of the autoimmune pie.

What makes Merida's approach potentially different is the precision angle. Most autoimmune therapies still work by broadly dampening immune function, which helps with the disease but also leaves patients vulnerable to infections and other side effects. A platform that selectively eliminates disease-causing antibodies could represent a genuine leap forward, if the clinical data holds up.

The Elephant in the Room: Phase 1 Risk

And that's the catch. MER511 is only in Phase 1, the earliest stage of human testing. We're talking about basic safety and dosing data. The drug hasn't proven it works yet in a controlled efficacy trial.

Paying nearly $3 billion for a Phase 1 asset is like buying a restaurant after tasting one appetizer. The appetizer might be incredible, but you haven't seen the kitchen, met the full staff, or checked whether the plumbing works.

The milestone structure matters here. If most of that $2.875 billion is locked behind clinical and regulatory milestones, Lilly's actual risk is much smaller than the headline suggests. If MER511 fails in Phase 2, those milestone payments never get triggered. Lilly walks away bruised but not broken.

The Bigger Picture

Zoom out, and Lilly's 2026 strategy starts to look less like impulsive shopping and more like a calculated portfolio construction exercise. The company is placing multiple bets across different therapeutic areas and modalities: small molecules, vaccines, cell therapies, gene therapies, and now precision autoantibody degradation.

It's the pharmaceutical equivalent of index investing. No single acquisition needs to be a home run. Lilly just needs a few of these bets to pay off over the next decade, and the GLP-1 revenue stream gives it the financial cushion to absorb the ones that don't.

Wall Street seems cautiously on board. The consensus view is that Lilly is spending wisely rather than desperately, using its obesity windfall to build long-term therapeutic breadth. Whether Merida's approach to autoimmune disease turns out to be the real deal or an expensive science experiment won't be clear for years.

But at this rate, if there's a biotech company with a promising idea and a for-sale sign, Lilly's probably already on the phone.